Search Results - "FETY, Regine"

Relationship between 5‐fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy by Beneton, Maud, Chapet, Sophie, Blasco, Hélène, Giraudeau, Bruno, Boisdron‐Celle, Michèle, Deporte‐Fety, Régine, Denis, Fabrice, Narcisso, Bérangère, Calais, Gilles, Le Guellec, Chantal

“…What is already known about this subject • Dihydropyrimidine dehydrogenase (DPD) deficiency is currently evaluated as a means of identifying patients with a…”
Get full text

Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group by JOERGER, Markus, HUITEMA, Alwin D. R, SLEEBOOM, Henk P, IZQUIERDO, Miguel A, JODRELL, Duncan I, CALVERT, Hilary, BODDY, Alan V, HOLLEMA, Harry, FETY, Regine, VAN DER VIJGH, Wjfj. F, HEMPEL, Georg, CHATELUT, Etienne, RICHEL, Dick J, KARLSSON, Mats, WILKINS, Justin, TRANCHAND, Brigitte, SCHRIJVERS, Ad H. G. J, TWELVES, Christian, BEIJNEN, Jos H, SCHELLENS, Jan H. M, DITTRICH, Christian, PAVLIDIS, Nikolas, BRIASOULIS, Evangelos, VERMORKEN, Jan B, STROCCHI, Elena, MARTONI, Andrea, SORIO, Roberto

“…Purpose: Paclitaxel and carboplatin are frequently used in advanced ovarian cancer following cytoreductive surgery. Threshold models have been used to predict…”
Get full text

Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors by Ricolleau, Gabriel, Charbonnel, Catherine, Lodé, Laurence, Loussouarn, Delphine, Joalland, Marie-Pierre, Bogumil, Ralf, Jourdain, Sabine, Minvielle, Stéphane, Campone, Mario, Déporte-Fety, Régine, Campion, Loïc, Jézéquel, Pascal

“…Novel prognostic biomarkers are imperatively needed to help direct treatment decisions by typing subgroups of node‐negative breast cancer patients. The current…”
Get full text

Population pharmacokinetics of topotecan : intraindividual variability in total drug by MONTAZERI, Ashraf, BOUCAUD, Maude, CANAL, Pierre, CHATELUT, Etienne, LOKIEC, Francois, PINGUET, Frédéric, CULINE, Stéphane, DEPORTE-FETY, Régine, ALBIN, Nicolas, LAGUERRE, Brigitte, GOUPIL, Alain, BUGAT, Roland

“…The inter- and intraindividual variabilities in topotecan clearance (CL) were explored using a population pharmacokinetic approach. Total (lactone + hydroxy…”
Get full text

Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients : A Study by the EORTC-PAMM-NDDG by JOERGER, Markus, HUITEMA, Alwin D. R, SLEEBOOM, Henk P, IZQUIERDO, Miguel A, JODRELL, Duncan I, FETY, Régine, DE BRUIJN, Ernst, HEMPEL, Georg, KARLSSON, Mats, TRANCHAND, Brigitte, SCHRIJVERS, Ad H. G. J, TWELVES, Chris, RICHEL, Dick J, BEIJNEN, Jos H, SCHELLENS, Jan H. M, DITTRICH, Christian, PAVLIDIS, Nikolas, BRIASOULIS, Evangelos, VERMORKEN, Jan B, STROCCHI, Elena, MARTONI, Andréa, SORIO, Roberto

“…To investigate the population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients. Sixty-five female patients…”
Get full text

Dose and time dependencies of 5-fluorouracil pharmacokinetics by Terret, Catherine, Erdociain, Eric, Guimbaud, Rosine, Boisdron‐Celle, Michèle, McLeod, Howard L., Féty‐Deporte, Régine, Lafont, Thierry, Gamelin, Erick, Bugat, Roland, Canal, Pierre, Chatelut, Etienne

“…Objectives The purpose of this study was to examine the interpatient and intrapatient variability of the Michaelis‐Menten plasma parameters of 5‐fluorouracil…”
Get full text

Individual Adaptive Dosing of Topotecan in Ovarian Cancer by MONTAZERI, Ashraf, CULINE, Stéphane, CHATELUT, Etienne, LAGUERRE, Brigitte, PINGUET, Frédéric, LOKIEC, Francois, ALBIN, Nicolas, GOUPIL, Alain, DEPORTE-FETY, Régine, BUGAT, Roland, CANAL, Pierre

“…Purpose: To take into account relationships between topotecan area under the plasma concentration (AUC) versus time curve and percentage decrease of neutrophil…”
Get full text

Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas by FETY, R, ROLLAND, F, MILANO, G, BARBERI-HEYOB, M, HARDOUIN, A, CAMPION, L, CONROY, T, MERLIN, J.-L, RIVIERE, A, PERROCHEAU, G, ETIENNE, M.-C

“…A significant link between 5-fluorouracil (5FU) plasma concentration and its therapeutic activity has been demonstrated in colon and head and neck cancer…”
Get full text

Docetaxel combined with vinorelbine: phase I results and new study designs by Fumoleau, P, Féty, R, Delecroix, V, Perrocheau, G, Azli, N

“…This was a phase I dose-finding and pharmacokinetic study of vinorelbine (Navelbine) and docetaxel (Taxotere) as first-line chemotherapy for metastatic breast…”
Get more information

Common DPYD mutation associated with 5-fluorouracil toxicity detected by PCR-mediated site-directed mutagenesis by Jézéquel, P, Joalland, M P, Milano, G, Lanoë, D, Ricolleau, G, Marie-Christine, E, Deporte-Fety, R

Get full text

UFT plus oral calcium folinate/vinorelbine for advanced breast cancer by Fumoleau, P, Déporte-Fety, R, Kerbrat, P, Laguerre, B

“…This phase I study was undertaken to define the maximum tolerated dose, dose-limiting toxicity, and recommended dosage of UFT (uracil and tegafur) plus oral…”
Get more information

Time course study of changes in the activity of the catecholamine synthesizing enzymes in the rat medulla oblongata after intraventricular injection of 6-hydroxydopamine by Fety, R, Renaud, B

“…Recent data have shown that 5 days after intraventricular injection of 6-hydroxydopamine (6-OHDA), the tyrosine hydroxylase activity (TH) was increased within…”
Get more information

Changes in tyrosine hydroxylase and dopamine-beta-hydroxylase activities but not in phenylethanolamine-N-methyltransferase activity within central adrenaline neurons after 6-hydroxydopamine administration by Fety, R, Lambas-Senas, L, Chamba, G, Renaud, B

“…By using a new microdissection procedure allowing the noradrenaline (NA) and adrenaline (A) cell groups of the A2-C2 region to be sampled preferentially, it…”
Get more information

Gene Expression Profiles Discriminate between Pathological Complete Response and Resistance to Neoadjuvant FEC100 in Breast Cancer by MARIE MILLOUR, CATHERINE CHARBONNEL, FLORENCE MAGRANGEAS, STÉPHANE MINVIELLE, LOÏC CAMPION, WILFRIED GOURAUD, MARIO CAMPONE, RÉGINE DÉPORTE-FÉTY, YVES-JEAN BIGNON, FRÉDÉRIQUE PENAULT-LLORCA, PASCAL JÉZÉQUEL

“…Background: In breast cancer treatment, FEC100 (fluorouracil, epirubicin and cyclophosphamide) chemotherapy delivered in a neoadjuvant setting is still applied…”
Get full text

Central and peripheral changes in catecholamine-synthesizing enzyme activities after systemic administration of the neurotoxin DSP-4 by Féty, R, Misère, V, Lambàs-Señas, L, Renaud, B

“…In brain regions containing noradrenergic (NA) cell bodies or terminals, DSP-4 induces changes in the activity of catecholamine-synthesizing enzymes which…”
Get more information